Compound 21 for Preeclampsia
Trial Summary
What is the purpose of this trial?
Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during the preeclamptic pregnancy and persists postpartum, despite the remission of clinical symptoms. The purpose of this investigation is to determine the mechanisms contributing to this lasting blood vessel damage caused by reduced endothelial function in women who have had preeclampsia compared to women who had a healthy pregnancy. Identification of these mechanisms and treatment strategies may lead to better clinical management of cardiovascular disease risk in these women. The purpose of this study is to examine the microvascular differences in women who have had preeclampsia following activation of protective angiotensin receptors in the skin. This will help increase understanding of the mechanisms of angiotensin II receptors in these women, and how activation of these receptors may restore microvascular function. In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) the investigators examine the blood vessels in a dime-sized area of the skin.
Will I have to stop taking my current medications?
If you are currently taking antihypertensive or cholesterol-lowering medications, you cannot participate in this trial. The protocol does not specify about other medications, so it's best to discuss with the trial team.
What data supports the effectiveness of the drug Compound 21 for treating preeclampsia?
Research suggests that targeting the angiotensin receptors, like those affected by Compound 21, may have potential in treating preeclampsia. The angiotensin system is involved in blood pressure regulation, and variations in angiotensin receptor genes have been linked to preeclampsia, indicating that drugs affecting these receptors could be beneficial.12345
Is Compound 21 generally safe for humans?
How does Compound 21 differ from other drugs for preeclampsia?
Compound 21 is unique because it targets GPCRs (G protein-coupled receptors), which are promising candidates for treating preeclampsia, unlike other treatments that focus on different pathways. This approach could offer a new way to manage the condition by addressing specific receptor targets involved in the disease.12458
Eligibility Criteria
This trial is for women aged 18-45 who experienced preeclampsia between 12 weeks and 5 years ago. It's also open to those who had healthy pregnancies. Participants should not be currently pregnant, planning pregnancy, have a history of hypertension or metabolic disease before pregnancy, use tobacco, or take certain medications like antihypertensives or statins.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo intradermal microdialysis for the local delivery of compound 21 and L-NAME to the cutaneous microvasculature
Follow-up
Participants are monitored for changes in microvascular blood flow response and angiotensin receptor expression
Treatment Details
Interventions
- Compound 21 (Angiotensin II Receptor Agonist)